AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
dotinurad 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| urate transporter inhibitors | 5425 | 1285572-51-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Dotinurad, a novel selective urate reabsorption inhibitor, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1), which is expressed on the proximal renal tubules and is responsible for reabsorption of uric acid.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 38 | |||
| kinase-selectivity-class | ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK1,MAPK7,MAPK8,MARK4,PDK1,PDK4,SIK2,STK33,TEK | 17 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 23, 2020 | PMDA | Fuji Yakuhin |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M04AB06 | MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations increasing uric acid excretion |
| MeSH PA | D006074 | Gout Suppressants |
| MeSH PA | D014528 | Uricosuric Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| CHEBI has role | CHEBI:35845 | gout suppressant |
Related Drugs by ATC class:
M04AB Preparations increasing uric acid excretion 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperuricemia | indication | 35885006 | DOID:1920 |
| Gout | indication | 90560007 | DOID:13189 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 12 | Transporter | INHIBITOR | IC50 | 7.43 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| ATP-binding cassette sub-family G member 2 | Transporter | INHIBITOR | IC50 | 5.38 | SCIENTIFIC LITERATURE | ||||
| Solute carrier family 22 member 6 | Transporter | INHIBITOR | IC50 | 5.39 | SCIENTIFIC LITERATURE | ||||
| Solute carrier family 22 member 8 | Transporter | INHIBITOR | IC50 | 5.88 | SCIENTIFIC LITERATURE | ||||
| Cytochrome P450 2C9 | Enzyme | INHIBITOR | IC50 | 5.24 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D11071 | KEGG_DRUG |
| 305EB53128 | UNII |
| C5238059 | UMLSCUI |
| CHEBI:757931 | CHEBI |
| CHEMBL4594446 | ChEMBL_ID |
| 51349053 | PUBCHEM_CID |
| DB16145 | DRUGBANK_ID |
| 10438 | INN_ID |
| C000706811 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11389 | IUPHAR_LIGAND_ID |
| A1AIK | PDB_CHEM_ID |
Pharmaceutical products:
None